其他品牌 品牌
经销商厂商性质
苏州市所在地
FLOWTECH血管造影剂
面议Moregate FBSF-500澳洲血清
面议sigma试剂/Oxycodone-D3 solution
面议P-1033抑制剂
面议G-418 SULFATE 硫酸盐
面议Allele Biotech公司产品介绍/试剂代购
面议AG Scientific公司抗体介绍
面议AAT Bioquest公司荧光探针Rhod-4™使用说明
面议AAT Bioquest公司荧光探针Fluo-8®使用说明
面议AAT Bioquest荧光染料Cal-520使用方法
面议Blocking Solutions Background Suppression
面议Benefits of our US-Kit*
面议Anatrace公司产品订购,请联系苏州蚂蚁淘生物科技有限公司
自上世纪80年代末以来,的研究机构、学术机构和工业客户一直信任Anatrace,相信它能提供高纯度的洗涤剂、油脂、海关,当然还有更高的标准。由于世邦魏理仕的私募股权投资,世邦魏理仕再次成为一家私营企业,我们现在将这些标准设定得比以往任何时候都要高。
作为膜蛋白结构生物学领域的佼jiao者,阿纳托瑞斯的产品因其*的纯分子和其背后的严格的化学原理而备受青睐。从设计用来破坏细胞膜的化合物到稳定或溶解不稳定大分子和蛋白质的产品,我们一直在提高标准。因此,你的结构研究,功能生物学工作,或化学合成项目将产生令人难以置信的可靠结果。这就是为什么在过去的5年里,出版物平均每年引用我们400多次。
随着我们大量的产品组合,我们的化学家可以开发专门的解决方案,以满足您*的规格。我们还可以提供定制的综合服务和专家分析工作,以帮助您自己的研究和开发团队。可能性是无限的——就像我们追求的*一样。
Anatrace公司产品订购
Developed at the Midwest Center for Structural Genomics as part of the Protein Structure Initiative - Most product crystallization conditions
MCSG: MCSG Suite
PART # | DESCRIPTION | UNIT SIZE | PRICE (USD) | QTY |
MCSG-2 | MCSG-2 Crystal Screen (1.7 ml block) | 1.7 ml | 236 |
| |
MCSG-3 | MCSG-3 Crystal Screen (1.7 ml block) | 1.7 ml | 236 |
| |
MCSG-4 | MCSG-4 Crystal Screen (1.7 ml block) | 1.7 ml | 236 |
| |
MCSG-1 | MCSG-1 Crystal Screen (1.7 ml block) | 1.7 ml | 236 |
| |
MCSG-4T | MCSG-4 Crystal Screen (10 ml tubes) | 10 ml | 618 |
| |
MCSG-1T | MCSG-1 Crystal Screen (10 ml tubes) | 10 ml | 618 |
| |
MCSG-3T | MCSG-3 Crystal Screen (10 ml tubes) | 10 mL | 618 |
| |
MCSG-2T | MCSG-2 Crystal Screen (10 ml tubes) | 10 ml | 618 |
|
PRODUCT DESCRIPTIONTECHNICAL DOCUMENTATIONREQUIRED / RELATED PRODUCTS
Storage Conditions: 4-20 C
pH: Varies
Conductance: Varies
Appearance: Clear Solutions
The MCSG Suite has been developed at the Midwest Center for Structural Genomics. As part of the Protein Structure Initiative, MCSG has been instrumental in the development of rapid, integrated and cost-effective methods for protein structure determination via X-ray crystallography.
Through extensive crystallization screening of more than 40,000 diverse proteins from both prokaryotic and eukaryotic organisms, researchers at the MCSG have derived the most up-to-date set of crystallization conditions for initial screening. These non-redundant conditions constitute the broadest coverage of crystallization space of any commercially available screen and are supported by a decade of experimental analysis and validation.
The complete MCSG suite (384 conditions) comprises of 4 screens of 96 unique conditions that are available either as deep-well blocks (1.7 mL per well) or tubes (10 ml). Conditions 1-288 are organized in order of decreasing crystal productivity in screens MCSG-1, MCSG-2 and MCSG-3. Thus MCSG-1:A1 condition has yielded the greatest number of unique crystals for all targets screened with the suite predecessors. The conditions that comprise MCSG-4 have been rationally selected to systematically sample regions of crystallization space for proteins requiring additional screening.
The end result is the best, first-pass screening suite possible, with: